Abstract. Lung metastasis is one of the important characteristics of salivary adenoid cystic carcinoma (SACC). Although activation of extracellular signal-regulated kinase 1/2 (ERK1/2) pathway may be associated with cancer progression in some malignant tumors, its roles in lung metastasis of SACC remains unclear. We examined the expression of activated ERK1/2 in SACC-LM with high lung-metastatic rate and SACC-83 with low lung-metastatic rate, as well as in the tissues from lung-metastatic and nonmetastatic groups of SACC patients. Western blot analysis indicated that SACC-LM exhibited higher expression of activated ERK1/2 than SACC-83. Similarly, immunohistochemistry showed that expression of activated ERK1/2 was detected in 73% (8/11) of the primary tissues from SACC patients with lung metastasis, while only 25% (3/12) of the primary tissues from SACC patients without lung metastasis (P<0.05). Furthermore, we examined the effects of U0126, a specific inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK), on migration and invasion in SACC-LM cells, showing U0126 not only inactivated ERK1/2, but also inhibited migration and invasion of SACC-LM. The present findings suggested that the elevated expression of activated ERK1/2 may play a role in lung metastasis of salivary adenoid cystic carcinoma.
Introduction
As one of the most common malignant tumors of salivary glands, salivary adenoid cystic carcinoma (SACC) has some unique characteristics such as neurotropic, infiltrative growth and distant metastasis (1, 2) . Unlike some other epithelial malignancies with poor prognosis, SACC has a good 5-year survival rate (~80%), but 10-and 20-year survival rate drops to a lower level (3, 4) .
Ninety percent of deaths from solid tumors attribute to metastases (5) . For SACC patients, distant metastasis is a crucial prognostic factor (6) . Previously, we established a human salivary adenoid cystic carcinoma cell line, SACC-83, from a patient suffering from adenoid cystic carcinoma in sublingual gland (7) . SACC-83 has a relatively lower lungmetastatic rate that only 33.3% of the nude mice showed lung metastases three months after injection of the tumor cells into the tail vein of nude mice. Further, a derived cell line SACC-LM with higher lung-metastatic rate was generated from SACC-83 by repeating of culture and injection of the lung metastatic tumor cells into the tail vain of nude mice. The metastatic rate was finally 85.0% for SACC-LM while only 33.3% for SACC-83.
Mitogen activated protein kinase (MAPK) pathways are well characterized and believed to have close relationship with metastases, as they regulate many courses involved in cancer progression, such as inducing proteolytic enzymes, initiating several pro-survival genes, maintaining growth, promoting cell migration and invasion (8) (9) (10) . Accumulating data show that it is significantly activated in many invasive malignant tumors including carcinomas of the breast, colon, kidney and lung (11) (12) (13) (14) .
Among the three distinct MAPK signaling pathways [extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun Nterminal kinase/stress-activated protein kinase (JNK/SAPK), and p38], deregulation of ERK1/2 is observed in ~1/3 of all human cancers (15) . ERK1/2 activities are often shown to increase in metastatic tumors. For instance, the invasive breast cancer cell lines exhibit constitutively higher expression of activated ERK1/2 compared with the non-invasive breast cancer cells and a significant positive association exists between activated ERK1/2 and lymph node metastases of breast cancer (16) . In addition, the level of activated ERK1/2 increases with escalating tumor stage in prostate cancer, suggesting activation of ERK1/2 signal pathway is also associated with progression of prostate cancer (17) . However, the relationship of ERK1/2 pathway with lung-metastatic rate of SACC has not been defined.
In the present study, we examined the expression of activated ERK1/2 in SACC-83 with lower lung-metastatic rate and SACC-LM with higher lung-metastatic rate, as well as in the lung-metastatic and non-metastatic groups of SACC primary tissues. Furthermore, U0126, a specific inhibitor of mitogen activated protein kinase kinase 1/2 (MEK1/2), was applied to SACC-LM to elucidate the role of activated ERK1/2 in cell migration and invasion.
Materials and methods
Cell culture. SACC-83 and SACC-LM, previously established in our laboratory, were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, Utah, USA), 100 U/ml penicillin and 100 U/ml streptomycin at 37˚C in a humidified atmosphere of 5% CO 2 .
Patients and samples. Formalin-fixed, paraffin-embedded tissue blocks of primary SACC from 1995 to 2007 were retrieved and the corresponding H&E stained sections were reviewed in Department of Oral Pathology, Peking University Hospital of Stomatology. According to WHO classification of salivary gland, 23 SACC samples (9 cribriform type, 9 tubular type and 5 solid type) were selected. Clinical data including gender, age, lesion sites and conditions of lung metastasis were evaluated by reviewing medical charts and pathological records and summarized in Table I . The lung metastatic group was defined as the SACC patients developed lung metastases in 5 years after surgery while the non-metastatic group represented those patients who were free of lung metastases at 5 years.
In vitro wound closure assay. Following serum deprivation overnight, confluent monolayers of SACC cells were scratched with a yellow pipette tip to create wounded areas with distance of 400-600 μm. Wounded monolayers were incubated for 24 h in serum-free medium with vehicle (DMSO) or 10 μM U0126 (Promega, Madison, WI, USA). Wounded monolayers were photographed (x40) at 0 and 24 h after scratching. In vitro wound closure was represented by the decreased distance remaining uncovered by cells. Average rates of wound closure were calculated as the equation of decreased distance/incubated time. Data are presented as mean ± standard deviation from three independent experiments. To inhibit cell proliferation, parallel experiments were conducted with the addition of 0.5 μg/ml of mitomycin C. Migratory activity was assessed by the rate of wound closure in the presence of mitomycin C, while proliferative activity was determined as the rate of wound closure in the absence of mitomycin C subtracts the rate of wound closure in the presence of mitomycin C.
Transwell invasion and migration assays. Cell invasion assays were performed using Transwell chambers (Corning Costar, Rochester, NY, USA) containing a polycarbonate membrane filter (6.5 mm diameter, 8 μm pore size). In a preliminary cell invasion assays, various loads of extracellar matrix (ECM) gel (20-200 μg/well) were applied. The invaded cells of SACC-LM on the bottom surface of the membrane during 12 h were hardly detected unless 20 μg/well ECM gel load was added. Therefore, the membrane was coated with 20 μg ECM gel (Sigma-Aldrich, St. Louis, MO, USA) before use. The lower chamber contained 10% FBS medium. The overnight serumstarved SACC-LM cells were harvested and resuspended in serum-free medium with 0.2% BSA. After incubation with 10 μM U0126 or vehicle for 20 min, the cell suspension was seeded in chambers with 1x10 5 cells/well. After incubation for 12 h at 37˚C in 5% CO 2 , cells on the top surface of the membrane were wiped off with cotton swabs and the membrane were fixed and stained with crystal violet. Cells on the bottom surface of the membrane were examined with a light microscope at magnification of x200. Cells from 6-10 random fields across three replicate wells were captured for counting and the average number of invaded cells per field was represented activities of cell invasion. For cell migration assays, the same procedure was performed, except that Transwell chambers were not coated with ECM gel.
Western blot analysis. Western blot analysis was performed as previously described (18) . Briefly, cells were washed with PBS and lysised with lysis buffer, containing 1% Nonidet P-40, 5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 100 mM sodium orthovanadate and 1:100 protease inhibitors mixture (Sigma-Aldrich). The protein concentrations were determined using the BCA assay (Pierce, Rockford, IL, USA). Aliquots (40 μg) of the protein extracts were subjected to 12% SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The membrane was blocked in the block buffer (5% nonfat dry milk in TBS-T) for 1 h and probed with 1/500 dilution of anti-active-ERK1/2 antibodies (Cell Signaling Technology, Beverly, MA, USA) in the same buffer overnight at 4˚C. The membrane was washed extensively with TBS-T and then incubated with horseradish peroxidase-conjugated secondary antibodies against rabbit (Zymed, South San Francisco, CA, USA) for 1 h. After extensive washes with TBS-T, the membrane was visualized using the ECL kit (Applygen Technologies Inc., Beijing, P.R. China). To normalize the protein loading and transfer, the blots were stripped and reprobed with 1/1000 dilution of anti-ERK1/2 antibodies (total ERK1/2; Cell Signaling).
Immunohistochemistry. Paraffin-embedded, multiple tissue sections of 4 μm from the 23 SACC samples were placed on Poly-Lysine coated slides and then heated at 60˚C for 6 h, dried overnight at 37˚C, dewaxed in xylene and rehydrated in graded alcohol. PV-9000 Polymer Detection System for immunohistological staining (Zhongshan Goldenbridge Biotechnology Inc., Beijing, P.R. China) was used. To block endogenous peroxidase activity, sections were placed in 3% hydrogen peroxide for 10 min and treated with freshly prepared citrate buffer (pH 6.0) for 15 min in microwave oven for antigen retrieval. Tissue sections were incubated overnight at 4˚C with anti-active-ERK1/2 antibodies (1/100 dilution in PBS containing 2% BSA) after an initial incubation with the same antibodies at 37˚C for 30 min. After the overnight incubation, slides were treated with polymer helper for 20 min and poly-peroxidase anti-rabbit IgG for 30 min at room temperature. Finally, slides were incubated with diaminobenzidine chromogen solution (DAB) for 10 min. Each incubation step was followed by a 2 min PBS-T wash thrice. Finally, sections were counterstained with Mayer's hematoxylin and examined with a light microscope. Negative controls were treated in the same procedure but omitting the primary antibodies. The percentage of immunoreactive cells was estimated by randomly counting ~200 tumor cells from three different high-power fields (x400) within one specimen. Three semiquantitative classes were used to describe the number of stained cells: negative, <5% of the cells; moderate positive, 5-50% of the cells; intense positive, >50% of the cells. Both nuclear and cytoplasmic staining were examined.
Statistical analysis.
For studies on SACC cell lines, the results were expressed as mean ± SD and the significance of the differences between groups was determined by Student's t-test. For studies on SACC tissues in the lung-metastatic and non- Table I . Histological subtypes and clinical data.
Tumor type Gender Age (years) Site of lesion Lung metastasis 
----------------------------------------------------------------------------------------------------
a According to 5-year follow-up: +, positive and -, negative. Table II . Status of lung metastasis and activated ERK1/2 (p-ERK1/2) staining in SACC.
-----------------------------------------------------------------------------------------------------

-------------------------------------------------p-ERK positive b
Lung metastasis a n n (%) 
P-value -------------------------------------------------
(25) -------------------------------------------------
a According to 5-year follow-up.
b Including moderate positive staining and intense positive staining. c Fisher's exact test. metastatic groups, Fisher's exact test was used to test for differences in frequency of detection of active ERK1/2 between groups. P<0.05 was considered as statistically significant.
-------------------------------------------------
Results
Activated ERK1/2 more highly expressed in SACC-LM than in SACC-83.
Western blot showed the expression of activated ERK1/2 in SACC-LM was much higher than that in SACC-83 (Fig. 1A) . Moreover, U0126, a specific MEK inhibitor, abolished activation of ERK in SACC-LM at the concentration of 10 μM (Fig. 1B) .
MEK-specific inhibitor inhibits migration and proliferation of SACC-LM.
To determine the effects of activated ERK1/2 on migration of SACC-LM, in vitro wound closure assay and Transwell migration assay were applied. Incubation with 10 μM U0126 markedly decreased the wound closure of SACC-LM ( Fig. 2A) . Migratory and proliferative activity in wound closure assay with or without mitomycin C (an inhibitor of cell proliferation) were calculated as described in Materials and methods, showing that 10 μM U0126 inhibited migratory and proliferative activity of SACC-LM by 81.5 and 54.8%, respectively (Fig. 2B) . Besides, incubation with 10 μM U0126 decreased Transwell migration of SACC-LM after 12 h by 38.3% (P<0.0001) (Fig. 3A and B) , indicating increased activation of ERK1/2 in SACC-LM may contribute to the promoted cell migration.
MEK-specific inhibitor inhibits invasion of SACC-LM.
Incubation with 10 μM U0126 decreased Transwell invasion of SACC-LM during 12 h by 67.7% (P<0.0001) (Fig. 3A  and C) , suggesting raised expression of activated ERK1/2 may be also involved in promoted cell invasion in SACC-LM.
More frequently expression of activated ERK1/2 in primary tissues of lung-metastatic SACC. Formalin-fixed, paraffinembedded tissues from 12 non-metastatic and 11 lungmetastatic SACC patients were examined immunohistochemically for expression of activated ERK1/2. The results were summarized in Table II . Eight of 11 (73%) lungmetastatic SACC tissues showed positive staining for activated ERK1/2: three samples showed intense positive staining and five moderate positive staining. However, only three of 12 (25%) non-metaststic SACC tissues exhibited moderate positive staining for activated ERK1/2, while others were negative. The representative staining for activated ERK1/2 in lung-metastatic and non-metastatic group of cribriform, tubular and solid patterns are shown in Fig. 4 .
Discussion
The present study compared expression of activated ERK1/2 in SACC cell lines and tissues with different lung-metastatic potential and the results indicated that the samples of SACC with high lung-metastatic potential exhibited raised expression of activated ERK1/2.
Although ERK1/2 pathway has been broadly discussed in other malignant tumors, few studies have investigated the role of activated ERK1/2 in malignant tumors of salivary gland. Hu (19) reported that blockade of ERK1/2 inhibits expression levels of matrix metalloproteinases in adenoid cystic carcinoma cells, indicating ERK1/2 may be associated with invasive behaviors of SACC. Handra-Luca et al (20) found that ERK1/2 pathway is activated in mucoepidermoid carcinoma of salivary gland and suggested it may be positively associated with aggressive behavior as well as proliferative activity. In the present study, we found that activated ERK1/2 was more frequently and more highly expressed in lung-metastatic SACC tissues than in non-metastatic tumors, suggesting activation of ERK1/2 may have a mechanistic role in the metastatic progression of SACC.
A number of studies have demonstrated that ERK/MAPK pathway plays an important role in the regulation of tumor progression, including migration and invasion (8, 9) . As a fundamental process during normal embryonic development, wound repair, inflammatory response, cell migration also plays an important role in tumor metastasis (21) . Activation of ERK1/2 could promote cell migration through triggering the intracellular motility machinery, such as enhancing myosin light-chain kinase (MLCK) activity (22, 23) as well as regulating the small G proteins -Rac and Rho (24) . Cell invasion, crucial histological marker of metastatic tumors, is characterized with disruption of the integrity of the basement membrane. Through activation of a flock of transcriptional factors including activating protein-1 (AP-1), activated ERK1/2 regulated a number of proteolytic enzymes that degrade the basement membrane, such as matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA) (25, 26) . In some malignant tumors, persistent activation of ERK1/2 was considered to participate in extracellular matrix and basement-membrane degradation that advanced metastases (25, 27) . Previously, we reported that compared with the lower lung-metastatic rate cell line SACC-83, the higher lungmetastatic cell line SACC-LM exhibited higher ability in cell migration and invasion (28) . The present study further displayed that activated ERK1/2 was more highly expressed in SACC-LM than in SACC-83, and inactivation of ERK1/2 led to a significant inhibition of cell migration and invasion in SACC-LM. These findings suggested the markedly increased expression of activated ERK1/2 could be partially the cause for the increased cell migration and invasion of SACC-LM.
There are several possible mechanisms to induce activation of ERK/MAPK signaling. Growth factors and adhesion molecules often mediate receptor tyrosine kinase pathways and subsequent activation of ERK1/2 (29) . Previously, we found that the mRNA expression of epiregulin, a ligand of EGF receptor, was much higher in SACC-LM than in SACC-83 (28) . As a pan-EGFR ligand, epiregulin not only elicits a more potent mitogenic signal than epidermal growth factor (30) , but also participates in pulmonary metastatases in some invasive cancers (31, 32) . It has been reported that compared with EGF or TGF-·, epiregulin was more potent and effective in inducing significantly greater ERK1/2 activation (33). In addition, we also found that epiregulin induced great transient activation of ERK1/2 in SACC-83 (28) , suggesting that the elevated ERK1/2 activity in SACC-LM may be partly due to the increased expression of epiregulin.
In summary, significantly increased expression of activated ERK1/2 were found in SACC cell lines and tissues with higher lung-metastatic capability. Elevated activation of ERK1/2 may contribute to promoting cell migration and invasion in SACC cell line with higher lung-metastasis rate. The present findings suggest that increased expression of activated ERK1/2 could be associated with lung metastasis in salivary adenoid cystic carcinoma. 
